Premium
INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL
Author(s) -
Ferreri A.J.,
Sassone M.,
Miserocchi E.,
Govi S.,
Cecchetti C.,
Corti M.E.,
Calimeri T.,
Perrone S.,
Mappa S.,
Ponzoni M.,
Modorati G.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.137_2629
Subject(s) - medicine , rituximab , cd20 , lymphoma , clinical endpoint , surgery , gastroenterology , lymphoplasmacytic lymphoma , clinical trial , waldenstrom macroglobulinemia